5 results on '"Auclin, Edouard"'
Search Results
2. Real-life implementation and evaluation of the e-referral system SIPILINK
- Author
-
Nun, Aimé, Tropeano, Anne-Isabelle, Flamarion, Edouard, Roumy, Arnaud, Azais, Henri, Dehghani Kelishadi, Léa, Auclin, Edouard, Burgun, Anita, Katsahian, Sandrine, Ranque, Brigitte, Metzger, Marie-Hélène, and Tsopra, Rosy
- Published
- 2024
- Full Text
- View/download PDF
3. The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.
- Author
-
Seguí, Elia, Torres, Juan Manuel, Auclin, Edouard, Casadevall, David, Peiro Carmona, Sara, Aguilar-Company, Juan, García de Herreros, Marta, Gorría, Teresa, Laguna, Juan Carlos, Rodríguez, Marta, González, Azucena, Epaillard, Nicolas, Gavira, Javier, Bolaño, Victor, Tapia, Jose C., Tagliamento, Marco, Teixidó, Cristina, Arasanz, Hugo, Pilotto, Sara, and Lopez-Castro, Rafael
- Subjects
NEUTROPHIL lymphocyte ratio ,RESEARCH funding ,NEUTROPHILS ,CANCER patients ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,SEVERITY of illness index ,TUMOR markers ,TREATMENT effectiveness ,LONGITUDINAL method ,RESEARCH ,MEDICAL records ,ACQUISITION of data ,TUMORS ,INFLAMMATION ,CYTOKINES ,COVID-19 ,BIOMARKERS ,INTERLEUKINS ,DISEASE complications - Abstract
Simple Summary: Understanding the inflammatory interplay between cancer and COVID-19 infection is essential for improving patient care. Our study bridges a vital knowledge gap by exploring how a pre-existing tumor-induced inflammatory state can exacerbate the inflammatory response to COVID-19, adversely impacting COVID-19 outcomes. We introduce the FLARE score, a robust predictor derived from circulating inflammatory markers, that provides clinicians a practical tool for early identification of patients with cancer at higher risk of severe COVID-19 complications who might benefit most from immediate and intensive treatment strategies. Additionally, our study also underscore the role of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease. Purpose: Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. Methods: We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Results: Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. Conclusions: A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
- Author
-
Moreau, Mathilde, Alouani, Emily, Flecchia, Clémence, Falcoz, Antoine, Gallois, Claire, Auclin, Edouard, André, Thierry, Cohen, Romain, Hollebecque, Antoine, Turpin, Anthony, Pernot, Simon, Masson, Thérèse, Di Fiore, Frédéric, Dutherge, Marie, Mazard, Thibault, Hautefeuille, Vincent, Van Laethem, Jean-Luc, De La Fouchardière, Christelle, Perkins, Géraldine, Ben-Abdelghani, Méher, Sclafani, Francesco, Aparicio, Thomas, Kim, Stefano, Vernerey, Déwi, Taieb, Julien, Guimbaud, Rosine, Tougeron, David, Moreau, Mathilde, Alouani, Emily, Flecchia, Clémence, Falcoz, Antoine, Gallois, Claire, Auclin, Edouard, André, Thierry, Cohen, Romain, Hollebecque, Antoine, Turpin, Anthony, Pernot, Simon, Masson, Thérèse, Di Fiore, Frédéric, Dutherge, Marie, Mazard, Thibault, Hautefeuille, Vincent, Van Laethem, Jean-Luc, De La Fouchardière, Christelle, Perkins, Géraldine, Ben-Abdelghani, Méher, Sclafani, Francesco, Aparicio, Thomas, Kim, Stefano, Vernerey, Déwi, Taieb, Julien, Guimbaud, Rosine, and Tougeron, David
- Abstract
Background: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. Methods: In this multicenter study, we included patients with advanced dMMR/MSI-H non-colorectal digestive tumors treated with chemotherapy and/or ICIs. Patients were divided retrospectively into two groups, a CT group and an immunotherapy (IO) group. The primary endpoint was progression-free survival (PFS). A propensity score approach using the inverse probability of treatment weighting (IPTW) method was applied to deal with potential differences between the two groups. Results: 133 patients (45.1/27.1/27.8% with gastric/small bowel/other carcinomas) were included. The majority of patients received ICI in 1st (29.1%) or 2nd line (44.4%). The 24-month PFS rates were 7.9% in the CT group and 71.2% in the IO group. Using the IPTW method, IO treatment was associated with better PFS (HR=0.227; 95% CI 0.147–0.351; p < 0.0001). The overall response rate was 26.3% in the CT group versus 60.7% in the IO group (p < 0.001) with prolonged duration of disease control in the IO group (p < 0.001). In multivariable analysis, predictive factors of PFS for patients treated with IO were good performance status, absence of liver metastasis and prior primary tumor resection, whereas no association was found for the site of the primary tumor. Conclusions: In the absence of randomized trials, our study highlights the superior efficacy of ICI compared with standard-of-care therapy in patients with unresectable or metastatic dMMR/MSI-H non-colorectal digestive cancer, regardless of tumor type, with acceptable toxicity., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2024
5. A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial.
- Author
-
Samaille T, Falcoz A, Cohen R, Laurent-Puig P, André T, Taieb J, Auclin E, and Vernerey D
- Abstract
Background: We assessed the added value of incorporating carcinoembryonic antigen (CEA) to circulating tumor DNA (ctDNA) and pathological TN (pTN) stage for risk classification in stage 3 colon cancer (CC)., Patients and Methods: We retrospectively analyzed postoperative CEA values in patients with CC from the IDEA-France phase 3 trial. The relation between disease-free survival (DFS) and CEA was modeled through restricted cubic splines. Prognostic value of CEA, ctDNA, and pTN was assessed with the Kaplan-Meier method. Multivariate analysis was used to identify prognostic and predictive factors for DFS., Results: Among 696 patients (35%), CEA values were retrievable, and for 405 (20%) both CEA and ctDNA were available. An optimized CEA threshold of 2 ng/mL was identified, the 3-year DFS was 66.4% for patients above the threshold and 80.9% for those below (HR, 1.74; 95% CI, 1.33-2.28, P < .001). In multivariate analysis, CEA ≥ 2 ng/mL contributed significantly to model variability, becoming an independent prognostic factor for DFS (HR, 1.82; 95% CI,1.27-2.59), alongside ctDNA (HR, 1.88; 95% CI, 1.16-3.03) and pTN (HR, 1.78; 95% CI, 1.24-2.54). A novel integrated risk classification combining CEA, ctDNA, and pTN stage reclassified 19.8% of pT4/N2 patients as low risk and 2.5% of pT3/N1 patients as high risk. This new classification demonstrated the 3-year DFS of 80.8% for low-risk patients and 55.4% for high-risk patients (HR, 2.66, 95% CI, 1.84-3.86, P < .001)., Conclusions: Postoperative CEA value is a prognostic factor for DFS in stage 3 CC, independently of ctDNA and pTN. It advocates for systematic reporting in future adjuvant trials. Integrating both biomarkers with pTN could refine risk classification in stage 3 CC., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.